GOOD JENNIFER L 4

4 · RHYTHM PHARMACEUTICALS, INC. · Filed Sep 19, 2024

Form 4

Period: 2024-09-17

Director

Transactions

Exercise/Conversion
Common Stock
2024-09-17$18.99/sh+7,501$142,444→ 34,751 total
Exercise/Conversion
Common Stock
2024-09-17$22.93/sh+15,000$343,950→ 18,000 total
Exercise/Conversion
Common Stock
2024-09-17$21.37/sh+9,250$197,673→ 27,250 total
Exercise/Conversion
Stock Option (right to buy)
2024-09-17−15,000→ 0 total
Exercise: $22.93Exp: 2029-06-18→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-09-17−7,501→ 0 total
Exercise: $18.99Exp: 2031-06-08→ Common Stock (7,501 underlying)
Sale
Common Stock
2024-09-17$52.40/sh−31,751$1,663,803→ 3,000 total
Exercise/Conversion
Stock Option (right to buy)
2024-09-17−9,250→ 0 total
Exercise: $21.37Exp: 2030-06-16→ Common Stock (9,250 underlying)

Footnotes (3)

[F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 22, 2024.
[F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $52.00 to $53.00. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
[F3]The option is fully vested and exercisable.

Documents

1 file